Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
Abstract Background Nivolumab, an immune checkpoint inhibitor, has revolutionized the treatment of many cancers. Due to its novel mechanisms of action, nivolumab induces a distinct profile of adverse events. Currently, the incidence and risk of developing serious adverse events (SAEs) or fatal adver...
I tiakina i:
| Ngā kaituhi matua: | , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
BMJ Publishing Group
2018-10-01
|
| Rangatū: | Journal for ImmunoTherapy of Cancer |
| Ngā marau: | |
| Urunga tuihono: | http://link.springer.com/article/10.1186/s40425-018-0421-z |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|